(1) Has it even been tested yet in patients who are not positive for EML4-ALK? How do we know that crizotinib's efficacy is limited to these patients?
(2) My main point is not that ALK is not a valid target, but when you have a drug that is targeting multiple pathways how exactly do you know how much antitumor activity is attributable to each pathway?
Market Data 
Markets 
AI
